Prelude Therapeutics Incorporated(PRLD)

$6.63—

Chart

Prelude Therapeutics Incorporated(PRLD)

NASDAQ

$6.63—

Chart Studio

PRLD(PRLD)

PRLD

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.16

Nov 11, 2026 · Reports before open

Revenue Estimate

$35M

FY2028E EPS$0.69

FY2029E EPS$0.22

Analyst Sentiment

Wall St. Consensus

Hold

8 analysts·Limited coverage

Score

5 Buy (63%)1 Hold (13%)2 Sell (24%)

Rating Breakdown

Strong Buy

00%

Buy

563%

Hold

113%

Sell

225%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$8.00

+20.7%

Consensus

$8.00

+20.7%

Bull

$8.00

+20.7%

12-Month Target Range8 analysts

$8.00$8.00$8.00

Current $6.63Consensus

Current Price

$6.63

Upside to Consensus

$1.37

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+24.20%

EPS—

FY2028

Rev+252.98%

EPS—

FY2029

Rev-50.00%

EPS-68.12%

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$46M	$57M	$200M	$100M	$100M
Low	$28M	$13M	$122M	$61M	$61M
High	$63M	$100M	$278M	$139M	$139M
EBITDA Avg	$9M	$11M	$40M	$20M	$20M
Low	$6M	$3M	$24M	$12M	$12M
High	$13M	$20M	$56M	$28M	$28M
EBIT Avg	$9M	$11M	$40M	$20M	$20M
Low	$6M	$3M	$24M	$12M	$12M
High	$13M	$20M	$56M	$28M	$28M
Net Income Avg	$-23M	$-31M	$53M	$17M	$49M
Low	$-35M	$-47M	$26M	$8M	$24M
High	$-11M	$-15M	$80M	$25M	$74M
EPS Avg	$-0.30	$-0.41	$0.69	$0.22	$0.64
Low	$-0.45	$-0.61	$0.34	$0.11	$0.32
High	$-0.15	$-0.20	$1.04	$0.33	$0.96
Analysts (Rev / EPS)	1 / 1	2 / 1	1 / 1	1 / 1	1 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	$35M	$2M	$5M	$6M	$3M	$7M	$8M	$8M
Low	$34M	$2M	$5M	$6M	$3M	$7M	$8M	$8M
High	$36M	$2M	$5M	$6M	$3M	$7M	$8M	$8M
EBITDA Avg	$7M	$379,333	$925,199	$1M	$541,199	$1M	$2M	$2M
Low	$7M	$379,333	$925,199	$1M	$541,199	$1M	$2M	$2M
High	$7M	$379,333	$925,199	$1M	$541,199	$1M	$2M	$2M
EBIT Avg	$7M	$379,333	$925,199	$1M	$541,199	$1M	$2M	$2M
Low	$7M	$379,333	$925,199	$1M	$541,199	$1M	$2M	$2M
High	$7M	$379,333	$925,199	$1M	$541,199	$1M	$2M	$2M
Net Income Avg	$11M	$-17M	$-15M	$-16M	$-20M	$-23M	$-33M	$-34M
Low	$11M	$-17M	$-15M	$-16M	$-20M	$-23M	$-33M	$-34M
High	$11M	$-17M	$-15M	$-16M	$-20M	$-23M	$-33M	$-34M
EPS Avg	$0.11	$-0.17	$-0.15	$-0.16	$-0.20	$-0.23	$-0.34	$-0.35
Low	$0.11	$-0.17	$-0.15	$-0.16	$-0.20	$-0.23	$-0.34	$-0.35
High	$0.11	$-0.17	$-0.15	$-0.16	$-0.20	$-0.23	$-0.34	$-0.35
Analysts (Rev / EPS)	3 / 1	2 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Apr 27, 2026H.C. Wainwright

Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright

Target:$8.00

+70.2%from $4.70

Sep 10, 2024H.C. Wainwright

H.C. Wainwright Reiterates Neutral Rating on Prelude Therapeutics (PRLD)

Target:$5.00

-3.3%from $5.17

Jun 20, 2024Barclays

Prelude Therapeutics downgraded to Underweight from Equal Weight at Barclays

Target:$3.00

-22.5%from $3.87

Mar 13, 2024JMP Securities

JMP Securities Starts Prelude Therapeutics (PRLD) at Market Outperform, 'Precision Targeting of SMARCA Drives Cell Kill'

Target:$7.00

+51.5%from $4.62

Nov 17, 2022H.C. Wainwright

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $15

Target:$15.00

+94.8%from $7.70

Nov 15, 2022Morgan Stanley

Morgan Stanley Maintains Equal-Weight on Prelude Therapeutics, Lowers Price Target to $10

Target:$10.00

+23.5%from $8.10

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance